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Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes
Abstract
Insulin resistance and β-cell failure are the major defects in type-2 diabetes mellitus (T2DM).
However, the molecular mechanisms linking these two defects remain unknown. Elevated levels of apolipoprotein CIII (apoCIII) are associated, not only with insulin resistance, but also with cardiovascular disorders and inflammation. We now demonstrate that local apoCIII production is connected to pancreatic islet insulin resistance and β-cell failure. An increase in islet apoCIII causes deranged regulation of β-cell cytoplasmic free Ca 2+ -concentration ([Ca   2+ ] i ), increased mitochondrial metabolism, apoptosis and promotion of a local inflammatory milieu. Decreasing apoCIII in vivo results in improved glucose tolerance and pancreatic apoCIII knock-out islets transplanted into diabetic mice, with high systemic levels of the apolipoprotein, demonstrate a normal [Ca 2+ ] i response pattern and no hallmarks of inflammation. Hence, under conditions of islet insulin resistance locally produced apoCIII is an important diabetogenic factor responsible for β-cell incapacitation and may constitute a novel target for the treatment of T2DM.
Significance statement
We now demonstrate that an increase in apolipoprotein CIII (apoCIII) within the islets of Langerhans, as a consequence of local insulin resistance, causes deranged regulation of β-cell cytoplasmic free Ca 2+ -concentration ([Ca 2+ ] i ), increased mitochondrial metabolism, apoptosis and promotion of an intra-islet inflammatory milieu. Decreasing apoCIII in vivo in animals with insulin resistance results in improved glucose tolerance and pancreatic apoCIII knockout islets transplanted into diabetic mice, with high systemic levels of the apolipoprotein, demonstrate a normal [Ca 2+ ] i response pattern and no hallmarks of inflammation. Hence, under conditions of islet insulin resistance locally produced apoCIII is an important diabetogenic factor responsible for β-cell incapacitation and may constitute a novel target for the treatment of T2DM.
\body Glucose homeostasis in mammals is tightly controlled by a balance between peripheral tissue insulin sensitivity with corresponding glucose uptake, and regulated insulin secretion by pancreatic β-cells. If this balance is disturbed diabetes develops. The progression of type-2 diabetes mellitus (T2DM) occurs in phases. The initial phase is characterized by peripheral tissue insulin resistance with a β-cell compensatory response of increasing mass and insulin secretion. With prolonged hyperinsulinemia however, β-cells start to fail, causing defects in insulin secretion and eventually increased β-cell apoptosis (1, 2) . Although being crucial for the development of novel diabetes therapies, the direct link between insulin resistance and β-cell failure in T2DM is still not known.
Apolipoprotein CIII (apoCIII) resides on apoB lipoproteins and high density lipoproteins and regulates their metabolism by inhibiting lipoprotein lipase (3, 4) . The expression of apoCIII is increased by insulin deficiency and insulin resistance (5, 6) and recently it has been shown that hyperglycemia induces apoCIII transcription (7). On top of high levels of circulating triglycerides, mice overexpressing apoCIII are more susceptible to high-fat diet induced diabetes (8) . In humans, elevated levels of circulating apoCIII are associated with a number of adverse effects including cardiovascular problems, inflammation and insulin resistance (9, 10) . Conversely, humans with a life-long reduction of the apolipoprotein, due to mutations in the apoCIII gene, benefit from a favorable pattern of lipoproteins, increased insulin sensitivity and longevity, lower incidence of hypertension and protection against cardiovascular diseases (11, 12) .
We now show that apoCIII serves as a link between insulin resistance and β-cell failure in T2DM.
The mechanistic explanation is that specific insulin resistance within the pancreatic islet leads to local expression of apoCIII, resulting in an autocrine negative feedback loop for β-cell function and survival.
Results
Insulin signaling in ob/ob islets. The ob/ob mouse is known to progressively develop insulin resistance and a transient hyperglycemia (13) . Using this mouse model at the age of 4-12 weeks, we found that blood glucose and body weight increased progressively ( Fig. 1A and B) and that non-fasting insulin levels remained unchanged higher than in control animals ( Fig.   1C ). We determined the mRNA expression levels of gck, irs1, irs2, vamp2, snap25 and rab27a, genes that have been demonstrated to be controlled by insulin receptor (IR) activated phosphatidylinositol 3-kinase (PI3K) activity (14, 15) . All genes were downregulated in 12 weeks old ob/ob islets (Fig. 1D ). This is consistent with previous findings where a significantly reduced PI3K activity was found in islets from ob/ob mice at 12 weeks of age compared with islets from age-matched ob/lean littermates (16, 17) .
Progressive change in FoxO1-regulated gene expression in ob/ob islets over time. One of the ways in which insulin induces changes in gene expression is through the phosphorylation cascade of Akt and its downstream target forkhead transcription factor FoxO1. Insulinmediated activation of Akt leads to phosphorylation of FoxO1 with its nuclear exclusion and loss of transcriptional activity. This signaling cascade has been shown to be crucial in maintaining β-cell function and proliferation during either insulin resistance or insult/injury (18) (19) (20) . We determined levels of phospho-Akt and phospho-FoxO1 in ob/ob islets. There was a significant reduction in phospho-Akt (Ser473) and phospho-FoxO1 (Ser256) in islets from 12-weeks old ob/ob mice compared to islets from 4-weeks old ob/ob mice (Fig. 1E ). Total
Akt protein levels within these islets were not significantly different across time. Total FoxO1 protein levels in the islet could not be successfully measured because of poor signal from immunoblots, reflecting low expression of FoxO1. To circumvent this, we determined mRNA levels of FoxO1 and found no significant difference in all the age groups studied (Fig. 1E ).
The levels of nuclear FoxO1 was higher in islets from 12-weeks old ob/ob mice compared to islets from ob/lean. This was shown both in vivo, using the anterior chamber of the eye (ACE) transplantation technique (21), (Fig.1F ) and in vitro ( Fig.1G and H) . Hence, the simultaneous reduction of phospho-FoxO1 and increase in nuclear FoxO1 further corroborates the above described changes in ob/ob islet gene expression, since irs1, irs2, vamp2 and rab27a have been suggested to be repressed by FoxO1 (14) .
Insulin receptor-mediated repression of FoxO1 is pivotal in maintaining the balance between carbohydrate and fat metabolism in hepatocytes (3). In insulin-resistant hepatocytes, reduced FoxO1 phosphorylation, and hence its activation as a transcription factor, promotes the expression of apoCIII, a modulator of circulating triglycerides, glucose-6-phosphatase, a key gluconeogenic enzyme, and mttp1, a microsomal triglyceride transfer protein that is involved in lipoprotein assembly (22) . To explore if a similar mechanism occurs in ob/ob islets with declining levels of phospho-FoxO1, we determined the mRNA expression levels of the FoxO1 target genes apoCIII, g6pc2 (islet specific glucose-6-phosphatase) and mttp1. There was a significant increase in ob/ob islet mRNA expression of all three genes across time ( Fig. 2A and S1A and B). Together, these data suggest that insulin resistance at the islet level leads to a change in the expression of genes that are positively or negatively regulated by FoxO1.
Of these, apoCIII expression stands out as a novel islet factor ( Fig. 2A) . This is an important finding since this apolipoprotein is known to be involved in both β-cell dysfunction (23) and type-1 diabetes mellitus (24, 25) .
ApoCIII is increased in islets and serum in diabetes and systemically decreasing it in vivo improves the diabetic phenotype. As there was a three-fold increase in apoCIII mRNA levels in islets from 12-weeks old ob/ob mice, without any difference in liver and intestine apoCIII expression ( Fig. 2A , B and C), we decided to determine the systemic levels of apoCIII. The immunoblots showed increased apoCIII levels in serum of ob/ob mice ( Fig.   S2A and B). Given that liver is the main source of apoCIII, the higher levels of circulating apoCIII cannot be explained by the enhanced islet release of the apolipoprotein, but rather reflects reduced cellular uptake of triglyceride-rich (VLDL) remnants, similar to what has been previously reported (26) .
To explore the effects of decreasing apoCIII in vivo, ob/ob mice were treated with antisense oligonucleotides specific for apoCIII or an inactive control. These antisense oligonucleotides decrease apoCIII by more than 50% (Fig. 2D ). The lowering of apoCIII led to a reduced body weight and, most importantly, an improved glucose tolerance ( Fig. 2E and F) .
Immunostaining of islets from two healthy human subjects ( Fig.2G 1 and 2 ) and one T2DM patient ( Fig.2G 3) showed a higher degree of apoCIII positive cells in the T2DM islets, which is in accordance with the findings in the ob/ob mice.
ApoCIII overexpression increases [Ca
2+
] i in MIN6 cells. To corroborate the negative role of locally produced apoCIII on β-cell function, this apolipoprotein was overexpressed in the insulin-secreting cell line MIN6. Hampered by the ability of an antibody to recognize apoCIII in mouse liver sections and lysates, we resorted to a c-Myc tagged mouse apoCIII construct that allowed us to explore the localization of Myc-apoCIII within β-cells. Myc-apoCIII was detectable in media of the Myc-apoCIII-transfected cells after a 24-hour culture period, indicating that the synthesized apoCIII is being readily released into the extracellular medium (Fig. 3A) . No co-localization between Myc-apoCIII and insulin C-peptide could be detected in the transfected cells (Fig. 3B) ] i was also seen in nearby non-transfected cells in the same culture dish upon depolarization, which is likely to be explained by, in addition to the autocrine effect on the transfected cell itself, a paracrine effect of apoCIII. Although ob/ob islets are hyperplastic with massive β-cell proliferation, it does not rule out the presence of apoptosis in these islets. We determined the level of apoptosis in freshly isolated islets by measuring the activity of caspase 3/7. Apoptosis in islets from 12-weeks old ob/ob mice was significantly higher compared to islets from 4 weeks old ob/ob mice ( Fig. 4D ). This is consistent with a previous finding where reduced levels of phospho-FoxO1 in islets of New Zealand obese mice resulted in higher levels of apoptosis (27 ] i and an increase in β-cell apoptosis.
Reduced endogenous islet apoCIII in vitro and
Since liver is the predominant source of apoCIII it is necessary to clarify the extent to which an increased local production of the apolipoprotein within the islet will have an effect on the β-cell on top of that already provided by the liver. For this purpose we took the advantage of a global apoCIII -/-mouse (29) and the ACE as an in vivo experimental platform (21) . By transplanting islets from either knock-out or ob/ob mice into the eye of ob/ob mice with high serum levels of apoCIII, we created an in vivo model where both grafts were subjected to high systemic levels of the apolipoprotein, but only the ob/ob islets maintained a local production of apoCIII (Fig. 5A ). The islets were allowed to be in the eye for two weeks and during this time they developed a normal vascularization and hence were exposed to high systemic levels of apoCIII ( ] i , suggesting that the local islet production of apoCIII indeed has a detrimental effect on
] i handling ( Fig. 5C and D).
To further substantiate the significance of intra-islet levels of apoCIII for pancreatic β-cell function and survival, islets from apoCIII -/-mice and C57Bl/6 (B6) mice, as control, were transplanted into the eyes of B6 mice. Islets from apoCIII -/-mice were transplanted into the right eye and control islets from B6 mice were transplanted into the left eye of the same recipient mouse (Fig. 6A) . The islets were allowed to be vascularized and thereafter the transplanted mice were fed a HFD until they showed an impaired glucose tolerance. The levels of apoCIII were determined in serum and they were increased in B6 mice on HFD compared to mice fed normal chow (Fig. 6B ). In this unique experimental setup the very same animal served both as a control and an islet cell specific apoCIII knock out. It was thus possible to expose the two types of islets to exactly the same high systemic serum levels of apoCIII, originating from the liver, and the only difference was that the islets in the right eye
were not expressing apoCIII whereas those in the left eye did. The islets were imaged over time from 1 to 3 months post-transplantation (Fig. 6C ). As expected, the islets from the control B6 mice increased in size with time. In contrast, the apoCIII -/-islets had a smaller increase in size compared to the control islets, despite being exposed to the same high systemic levels of apoCIII ( Fig. 6C and D) . Importantly, vessel density, number of macrophages and NAD(P)H/FAD ratio were lower in the transplanted apoCIII -/-islets ( Fig.   6E ,F,G, H and I), suggesting that the lack of intra-islet apoCIII production prevents the HFDinduced inflammatory reaction.
Discussion
Diabetes is a severe, multifactorial and life-long disease spreading like an epidemic worldwide and where available treatment strategies are inadequate. T2DM is characterized by two major defects namely insulin resistance and β-cell failure, although the direct link between the two is not known. In the present study we report on apoCIII as the long sought for factor linking insulin resistance to β-cell failure in T2DM. The mechanistic explanation is that islet insulin resistance can promote local apoCIII production that negatively affects function and survival of the pancreatic β-cell, on top of the already high levels of the apolipoprotein promoted by the liver. This points to much wider negative effects of apoCIII in the pathogenesis of diabetes than previously assessed from cardiovascular studies.
T2DM develops as a consequence of the pancreatic β-cell no longer being able to cope with increased insulin resistance in the peripheral insulin target tissues, like the liver (30) . It is well-known that the expression of apoCIII is increased in the liver under conditions of insulin resistance (5). We and others have previously shown that also the pancreatic β-cell is equipped with insulin receptors and thereby applies insulin-induced signal-transduction for function and survival (15) . Importantly, we now demonstrate that the pancreatic islet can be subjected to insulin resistance leading to a progressive change in FoxO1-regulated gene expression in ob/ob islets over time. Hence, with prolonged hyperinsulinemia, insulin signaling at the islet level was compromised, similar to what has been reported for the β-cellspecific insulin receptor knockout mouse (βIRKO) and the β-cell-specific PI3K subunit p85α knockout mouse (βPik3r1) (14, 31) . In diabetic ob/ob mice there is therefore not only insulin resistance in the peripheral target tissues, leading to increased serum levels of apoCIII, but also islet insulin resistance, resulting in increased local production of the apolipoprotein.
Interestingly, we also found an increased number of apoCIII positive cells in islets from a patient with T2DM compared with islets from healthy individuals. In line with the overall negative effects reported for apoCIII (9, 10), our findings that systemically decreasing the levels of this apolipoprotein in vivo improves the diabetic phenotype are logical.
In order to clarify, at the molecular level, how local islet production of apoCIII affected the β- Finally, to prove that local islet production of apoCIII in vivo makes a difference for β-cell function and survival, on top of the already high systemic levels produced by the liver, we took the advantage of a global apoCIII -/-mouse (29) and the anterior chamber of the eye as an in vivo experimental platform (21) . In this way we could create a situation where the same animal served both as a control and a β-cell specific apoCIII -/-, which should be the ultimate experimental system compensating for any unspecific and/or compensatory effects.
Consequently, transplanting apoCIII -/-islets into one eye and control islets from ob/ob or B6 mice into the other eye of an ob/ob mouse or a HFD treated mouse, thereby exposing both types of islets to the same high systemic apoCIII levels originating from the liver, enabled us to show that islets lacking local production of apoCIII were protected and maintained normal function compared to islets expressing the apolipoprotein. In the latter case islets not only demonstrated unphysiological increases in [Ca 2+ ] i and apoptosis but also much higher in vivo proliferative activity, paralleled by an increase in vessel density, islet macrophages and NAD(P)H/FAD ratio, as a marker of β-cell metabolism. These changes are typical of an inflammatory milieu provided by apoCIII released locally within the islet as a consequence of insulin resistance (33) (34) (35) .
In the present study we have demonstrated that apoCIII can serve as a link between insulin resistance and β-cell failure in T2DM. Preventing insulin resistance at the islet level is thus crucial to preserve β-cell mass, especially during the late phase of T2DM where β-cells are progressively lost. Hence, local islet production of apoCIII may become a drugable target and thereby form the basis for a novel diabetes treatment regimen. It is of interest to note that there are human data from subjects with a genetic mutation in the apoCIII gene and thereby were either immediately used for mRNA/ protein analysis or were cultured overnight in RPMI 1640 medium supplemented with 10 % FCS, 2 mM glutamine as well as 100 U/ml and 100 µg/ml of penicillin and streptomycin, respectively.
Cell Culture. MIN6 cells, between passage 35 and 42, were cultured in DMEM containing 11.1 mM glucose and supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 10% FCS, and 75 µM β-mercaptoethanol at 5% CO 2 and 37°C. MIN6 cells were transfected using Lipofectamine (Invitrogen, USA) with the control expression construct containing tdTomato or c-Myc tagged mouse apoCIII construct for 24 h. All experiments were performed 48 h after transfection.
Biosensor construction and transduction of islets. pENTR2A.RIP1.FoxO1GFP was generated by replacing the cDNA for EGFP in pENTR2A.RIP1.EGFP with that of FoxO1-GFP obtained from pEGFP.N1.hFOXO1 (36) IRES-3Tomato was generated by introducing a cDNA encoding three copies of the red fluorescent protein dTomato (37) downstream of the IRES sequence in pIRES (Clontech, USA). The IRES-3Tomato cassette was then introduced into pENTR2A.RIP1.FoxO1GFP thus creating pENTR2A.RIP1.FoxO1GFP-IRES-3Tomato.
pENTR2A.RIP1.FoxO1(H215R)GFP-IRES-3Tomato was generated by replacing histidine (CAT) 215 by arginine (CGT) by site-directed mutagenesis by employing the QuikChange mutagenesis kit (Stratagene, USA) and respective oligonucleotides purchased from Sigma.
All constructions were verified by DNA sequencing. The expression cassette was transferred into the promoterless adenovirus plasmid pAd/PL-DEST (Invitrogen, USA) by the Gateway technique. The ViraPower Adenoviral Expression System (Invitrogen, USA) was used to generate a replication-deficient adenovirus, which was used for transduction of cells and islets. Islets from ob/lean and ob/ob mice were transduced with 10 7 pfu/ml of the biosensor encoding adenovirus.
RNA isolation and quantitative RT-PCR analysis.
Total RNA was isolated from sorted cells or isolated pancreatic islets using the RNAeasy Micro Kit (Qiagen, Germany). Briefly, cells were lysed by first using RLT lysis buffer followed by a spin Qiashredder lysis. For liver and intestine RNA isolation, tissue/cell disruption was first carried out by a hand-held rotorstator homogenizer in RLT lysis buffer followed by 1000 x g centrifugation for 5 min. 
Intraocular islet transplantation.
Isolated islets from ob/ob, apoCIII -/-and C57Bl/6 mice were transplanted into the anterior chamber of the eye (ACE) of ob/ob (n=8) or C57Bl6 (n=8) mice as described previously (21) . Biosensor transduced islets from ob/lean and ob/ob mice were transplanted into the ACE of 8 weeks old syngeneic littermate recipients.
In vivo and in vitro imaging of islets and image analysis. The islet grafts were imaged in vivo as previously described (21) Blood vessels were imaged directly after injection whereas macrophages were imaged 72 hours later.
Islet autofluorescence from NAD(P)H and FAD was determined by 2-photon laser-scanning microscopy using the same microscope setup as described above, but without loading with indicator (38) . The redox ratio NAD(P)H/FAD was calculated using LAS AF software (Leica Microsystems). Excitation wavelengths were 760 nm for NAD(P)H and 900 nm for FAD. ] i upon membrane depolarization using 25 mM KCl (n=3-4). Data presented as mean ± sem, ** p<0.01 by student´s t-test. ]i when the islets are depolarized with KCl (n=11 and 9, respectively). *p <0.05 by student´s t-test. 
